Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
American Heart Association (AHA) Scientific Sessions 2021
November 13 - 15, 2021; Virtual
November 13 - 15, 2021Virtual
AHA 2021Obicetrapib: CETP Inhibitor Impresses in LDL LoweringA new lipid-lowering agent in a class that had been written off by many is being developed by a group of academic experts, with new data showing large LDL reductions on top of high-intensity statins.
Medscape Medical News, November 24, 2021
AHA 2021Daily Oral PCSK9 Inhibitor Encouraging in Phase 1 TrialsWhat if the cholesterol-crushing efficacy of current PCSK9 inhibitors came in a pill instead of a syringe? That's one possibility for a Merck agent in the earliest stages of human trials.
Medscape Medical News, November 23, 2021
AHA 2021ACEI, ARBs in COVID-19: Be Aware of Acute Kidney InjuryThe largest randomized dataset yet of ACE inhibitors and angiotensin receptor blockers in COVID-19 shows reassuring results, but with a potential new link to kidney injury in hospitalized patients.
Medscape Medical News, November 22, 2021
Meeting Highlights At A Glance
AHA 2021 Highlights: Surgery and DrugsStudies on early valvular heart surgery and SGLT2 inhibitors in acute heart failure are the featured highlights from AHA 2021.
AHA 2021 Highlights: Patient CentricAmong the highlights: a strategy to lower blood pressure in rural communities, and studies on how coffee and alcohol affect
heart rhythm.
SAMSON Pins Most Muscle Pain With Statins on the Nocebo EffectSome patients really do get side effects, such as muscle pain, from statins, but the trial suggests that '90% of this symptomatic
burden is elicited by placebo tablets too,' researchers say.
Medscape Medical News, Nov 15, 2020
STRENGTH Trial Questions CV Benefit of High-Dose Omega-3sQuestions about the CV benefit of omega-3 fatty acids and the high-dose eicosapentaenoic acid product, Vascepa, have resurfaced
with results of the STRENGTH trial using a combination product, Epanova.
Medscape Medical News, Nov 15, 2020
SGLT1/2 Inhibitor Shows 'Spectacular' Safety, Efficacy in T2DSotagliflozin, a novel type of sodium-glucose cotransporter inhibitor, showed the diverse benefits this drug class provides
along with some new twists in a pair of international pivotal trials.
Medscape Medical News, Nov 18, 2020
Combined OCT, Cardiac MRI Unravels Root Cause in Most MINOCAThe multimodal imaging strategy has the potential to provide reassurance and clarity for women who present with an MI without
a major artery blockage, who are often left without a definitive diagnosis.